AZN•benzinga•
Reported Sunday, AstraZeneca's IMFINZI Regimen Reduces Risk Of Progression, Recurrence, Or Death By 29% In Early Gastric Cancer In Phase 3 MATTERHORN Trial
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga